Chapter 1. Introduction


1.1. Report description and scope

1.2. Research scope

1.3. Research methodology


1.3.1. Market research process

1.3.2. Market research methodology



Chapter 2. Executive Summary


2.1. Global Parkinsons disease therapeutics market, 2017 - 2023 (USD Billion)

2.2. Global Parkinsons disease therapeutics market: snapshot



Chapter 3. Parkinsons Disease Therapeutics Market- Market Dynamics


3.1. Introduction

3.2. Market Drivers


3.2.1. Global Parkinsons disease therapeutics market drivers: impact analysis

3.2.2. Increasing environmental factors genetic heredity

3.3. Market Restraints


3.3.1. Global Parkinsons disease therapeutics market restraints: impact analysis

3.3.2. Patent expiration of key branded drugs and side-effects associated with therapeutic drugs

3.4. Opportunities


3.4.1. Promising product pipeline represents the potential business development opportunities

3.5. Porters five forces analysis


3.5.1. Bargaining power of suppliers

3.5.2. Bargaining power of buyers

3.5.3. Threat from new entrants

3.5.4. Threat from new substitutes

3.5.5. Degree of competition

3.6. Market Attractiveness Analysis


3.6.1. Market attractiveness analysis, by drug class segment

3.6.2. Market attractiveness analysis, by route of administration segment

3.6.3. Market attractiveness analysis, by distribution channel segment

3.6.4. Market attractiveness analysis, by regional segment



Chapter 4. Global Parkinsons Disease Therapeutics Market- Competitive Landscape


4.1. Company market share analysis


4.1.1. Global Parkinsons disease therapeutics market: company market share, 2017

4.2. Strategic development


4.2.1. Acquisitions mergers

4.2.2. New therapy launch

4.2.3. Agreements, partnerships, collaborations and joint ventures

4.2.4. Research and development and regional expansion

4.3. Price trend analysis



Chapter 5. Global Parkinsons Disease Therapeutics Market- Drug Class Segment Analysis


5.1. Global Parkinsons disease therapeutics market: drug class overview


5.1.1. Global Parkinsons disease therapeutics market revenue share, by drug class, 2017 and 2023

5.2. Levodopa Combination


5.2.1. Global Parkinsons disease therapeutics market for levodopa combination, 2017 - 2023 (USD Billion)

5.3. Dopamine Agonists


5.3.1. Global Parkinsons disease therapeutics market for dopamine agonists, 2017 - 2023 (USD Billion)

5.4. Monoamine Oxidase B (MAO-B) Inhibitors


5.4.1. Global Parkinsons disease therapeutics market for monoamine oxidase B (MAO-B) Inhibitors, 2017 - 2023 (USD Billion)

5.5. Anticholinergic Drugs


5.5.1. Global Parkinsons disease therapeutics market for anticholinergic drugs, 2017 - 2023 (USD Billion)

5.6. Catechol-O-Methyltransferase (COMT) Inhibitors


5.6.1. Global Parkinsons disease therapeutics market for catechol-o-methyltransferase (COMT) inhibitors, 2017 - 2023 (USD Billion)

5.7. Others


5.7.1. Global Parkinsons disease therapeutics market for others, 2017 - 2023 (USD Billion)



Chapter 6. Global Parkinsons Disease Therapeutics Market- Route of Administration Segment Analysis


6.1. Global Parkinsons disease therapeutics market: route of administration overview


6.1.1. Global Parkinsons disease therapeutics market revenue share, by route of administration, 2017 and 2023

6.2. Oral


6.2.1. Global Parkinsons disease therapeutics market for oral, 2017 - 2023 (USD Billion)

6.3. Transdermal


6.3.1. Global Parkinsons disease therapeutics market for independent transdermal, 2017 - 2023 (USD Billion)

6.4. Subcutaneous


6.4.1. Global Parkinsons disease therapeutics market for subcutaneous, 2017 - 2023 (USD Billion)

6.5. Intestinal Infusion


6.5.1. Global Parkinsons disease therapeutics market for intestinal infusion, 2017 - 2023 (USD Billion)



Chapter 7. Global Parkinsons Disease Therapeutics Market- Distribution Channel Segment Analysis


7.1. Global Parkinsons disease therapeutics market: distribution channel overview


7.1.1. Global Parkinsons disease therapeutics market revenue share, by distribution channel, 2017 and 2023

7.2. Hospital Pharmacy


7.2.1. Global Parkinsons disease therapeutics market for hospital pharmacy, 2017 - 2023 (USD Billion)

7.3. Retail Pharmacy


7.3.1. Global Parkinsons disease therapeutics market for retail pharmacy, 2017 - 2023 (USD Billion)

7.4. Online Sales


7.4.1. Global Parkinsons disease therapeutics market for online sales, 2017 - 2023 (USD Billion)



Chapter 8. Global Parkinsons Disease Therapeutics Market- Regional Segment Analysis


8.1. Global Parkinsons disease therapeutics market: regional overview


8.1.1. Global Parkinsons disease therapeutics market revenue share, by region, 2017 and 2023

8.2. North America


8.2.1. North America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.2.2. North America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.2.3. North America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.2.4. U.S.


8.2.4.1. U.S. Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.2.4.2. U.S. Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.2.4.3. U.S. Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.2.5. Rest of North America


8.2.5.1. Rest of North America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.2.5.2. Rest of North America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.2.5.3. Rest of North America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.3. Europe


8.3.1. Europe Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.3.2. Europe Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.3.3. Europe Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.3.4. U.K.


8.3.4.1. U.K. Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.3.4.2. U.K. Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.3.4.3. U.K. Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.3.5. Germany


8.3.5.1. Germany Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.3.5.2. Germany Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.3.5.3. Germany Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.3.6. France


8.3.6.1. France Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.3.6.2. France Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.3.6.3. France Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.3.7. Rest of Europe


8.3.7.1. Rest of Europe Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.3.7.2. Rest of Europe Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.3.7.3. Rest of Europe Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.4. Asia Pacific


8.4.1. Asia Pacific Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.4.2. Asia Pacific Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.4.3. Asia Pacific Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.4.4. China


8.4.4.1. China Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.4.4.2. China Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.4.4.3. China Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.4.5. Japan


8.4.5.1. Japan Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.4.5.2. Japan Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.4.5.3. Japan Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.4.6. India


8.4.6.1. India Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.4.6.2. India Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.4.6.3. India Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.4.7. Rest of Asia Pacific


8.4.7.1. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.4.7.2. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.4.7.3. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.5. Latin America


8.5.1. Latin America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.5.2. Latin America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.5.3. Latin America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.5.4. Brazil


8.5.4.1. Brazil Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.5.4.2. Brazil Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.5.4.3. Brazil Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.5.5. Mexico


8.5.5.1. Mexico Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.5.5.2. Mexico Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.5.5.3. Mexico Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.5.6. Rest of Latin America


8.5.6.1. Rest of Latin America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.5.6.2. Rest of Latin America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.5.6.3. Rest of Latin America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.6. Middle East and Africa


8.6.1. Middle East and Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.6.2. Middle East and Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.6.3. Middle East and Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.6.4. Saudi Arabia


8.6.4.1. Saudi Arabia Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.6.4.2. Saudi Arabia Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.6.4.3. Saudi Arabia Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.6.5. UAE


8.6.5.1. UAE Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.6.5.2. UAE Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.6.5.3. UAE Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.6.6. South Africa


8.6.6.1. South Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.6.6.2. South Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.6.6.3. South Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)

8.6.7. Rest of Middle East and Africa


8.6.7.1. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)

8.6.7.2. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)

8.6.7.3. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)



Chapter 9. Company Profile


9.1. Novartis AG


9.1.1. Overview

9.1.2. Financials

9.1.3. Therapy portfolio

9.1.4. Business strategy

9.1.5. Recent developments

9.2. F. Hoffmann-La Roche AG


9.2.1. Overview

9.2.2. Financials

9.2.3. Therapy portfolio

9.2.4. Business strategy

9.2.5. Recent developments

9.3. AbbVie, Inc.


9.3.1. Overview

9.3.2. Financials

9.3.3. Therapy portfolio

9.3.4. Business strategy

9.3.5. Recent developments

9.4. Teva Pharmaceutical Industries Ltd.


9.4.1. Overview

9.4.2. Financials

9.4.3. Therapy portfolio

9.4.4. Business strategy

9.4.5. Recent developments

9.5. UCB, Inc.


9.5.1. Overview

9.5.2. Financials

9.5.3. Therapy portfolio

9.5.4. Business strategy

9.5.5. Recent developments

9.6. STADA Arzneimittel AG


9.6.1. Overview

9.6.2. Financials

9.6.3. Therapy portfolio

9.6.4. Business strategy

9.6.5. Recent developments

9.7. GlaxoSmithKline Plc


9.7.1. Overview

9.7.2. Financials

9.7.3. Therapy portfolio

9.7.4. Business strategy

9.7.5. Recent developments

9.8. Valeant Pharmaceuticals International, Inc.


9.8.1. Overview

9.8.2. Financials

9.8.3. Therapy portfolio

9.8.4. Business strategy

9.8.5. Recent developments

9.9. Merck Co., Inc.


9.9.1. Overview

9.9.2. Financials

9.9.3. Therapy portfolio

9.9.4. Business strategy

9.9.5. Recent developments

9.10. Impax Laboratories, Inc.


9.10.1. Overview

9.10.2. Financials

9.10.3. Therapy portfolio

9.10.4. Business strategy

9.10.5. Recent developments